Allarity updates DRP technology with new patents and lab certification

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Allarity updates DRP technology with new patents and lab certification

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

September 30, 2026 9:00 AM EDT


- Recently awarded patents have solidified Allaritys strategy to leverage DRP to ensure the commercial exclusivity of stenoparib

TARPON SPRINGS, Fla., September 30, 2026 Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)a differentiated, dual PARP and WNT pathway inhibitor
today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparibs clinical development while expanding external partnership opportunities.

Allarity Therapeutics was established on its... More